However, Aurinia’s not-so-secret lead drug asset Voclosporin offers a compelling partnering opportunity.
A First Glance at This Hedge Fund Firm’s Strategic Q2 Moves in Biotech Sector
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has released its financial results for the second quarter ended June 30, 2017. Amounts, unless specified otherwise, are expressed …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) presented new duration of remission data from its global Phase IIB AURA-LV (AURA) study in lupus nephritis (LN) during …
Yesterday, drug maker Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced the beginning of Phase 3 trial AURORA of voclosporin, a medicine intended to treat lupus …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced that the first patient has been dosed in AURORA, the Company’s Phase 3 confirmatory clinical trial evaluating voclosporin …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is an all or nothing bet. The company’s future depends on its only pipeline asset Voclosporin, a drug candidate …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has released its financial results for the first quarter ended March 31, 2017. Amounts, unless specified otherwise, are expressed …
Last week, on April 20, during the National Kidney Foundation 2017 Spring Clinical Meeting in Orland, Florida, Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH) announced some …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares rose 7% to $7.49 in Friday’s trading session, after the drug maker presented additional 48-week results from its global Phase …
